JP6577569B2 - C−アリールグリコシド誘導体、その薬物組成物、及び調製方法 - Google Patents

C−アリールグリコシド誘導体、その薬物組成物、及び調製方法 Download PDF

Info

Publication number
JP6577569B2
JP6577569B2 JP2017505695A JP2017505695A JP6577569B2 JP 6577569 B2 JP6577569 B2 JP 6577569B2 JP 2017505695 A JP2017505695 A JP 2017505695A JP 2017505695 A JP2017505695 A JP 2017505695A JP 6577569 B2 JP6577569 B2 JP 6577569B2
Authority
JP
Japan
Prior art keywords
compound
solvent
mmol
reaction
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017505695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511383A5 (enExample
JP2017511383A (ja
Inventor
高大新
▲楊▼和平
王培�
Original Assignee
上海▲ディー▼▲ノア▼医▲薬▼科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海▲ディー▼▲ノア▼医▲薬▼科技有限公司 filed Critical 上海▲ディー▼▲ノア▼医▲薬▼科技有限公司
Publication of JP2017511383A publication Critical patent/JP2017511383A/ja
Publication of JP2017511383A5 publication Critical patent/JP2017511383A5/ja
Application granted granted Critical
Publication of JP6577569B2 publication Critical patent/JP6577569B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017505695A 2014-04-14 2015-04-01 C−アリールグリコシド誘導体、その薬物組成物、及び調製方法 Expired - Fee Related JP6577569B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410148116.X 2014-04-14
CN201410148116 2014-04-14
CN201410392098.X 2014-08-11
CN201410392098.XA CN105001213B (zh) 2014-04-14 2014-08-11 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
PCT/CN2015/075651 WO2015158206A1 (zh) 2014-04-14 2015-04-01 C-芳基糖苷衍生物、其药物组合物、制备方法及应用

Publications (3)

Publication Number Publication Date
JP2017511383A JP2017511383A (ja) 2017-04-20
JP2017511383A5 JP2017511383A5 (enExample) 2018-05-17
JP6577569B2 true JP6577569B2 (ja) 2019-09-18

Family

ID=54323473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017505695A Expired - Fee Related JP6577569B2 (ja) 2014-04-14 2015-04-01 C−アリールグリコシド誘導体、その薬物組成物、及び調製方法

Country Status (5)

Country Link
US (1) US9914724B2 (enExample)
EP (1) EP3133071B1 (enExample)
JP (1) JP6577569B2 (enExample)
CN (1) CN105001213B (enExample)
WO (1) WO2015158206A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001213B (zh) 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
CN105017236A (zh) * 2014-04-14 2015-11-04 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
CR20180109A (es) * 2015-07-20 2018-05-03 Genzyme Corp Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r)
CN106892948B (zh) * 2015-12-17 2022-07-26 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
CN106928040A (zh) * 2015-12-31 2017-07-07 上海医药工业研究院 Sglt2抑制剂中间体的制备方法
CN107720781B (zh) * 2017-11-30 2018-07-17 五莲森之林海藻有限公司 一种盐晶颗粒提取设备
WO2019185026A1 (zh) * 2018-03-30 2019-10-03 南京明德新药研发有限公司 作为SGLTs抑制剂的葡糖苷类衍生物及其应用
CN111471032B (zh) * 2019-01-24 2023-08-01 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物的合成方法及其中间体和应用
CN111471031B (zh) * 2019-01-24 2023-05-16 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物及其制备方法和应用
CN114585358B (zh) * 2019-07-26 2023-11-10 东宝紫星(杭州)生物医药有限公司 一种SGLTs/DPP4抑制剂及其应用
CN111269205B (zh) * 2020-02-19 2023-05-26 华侨大学 一种c-芳基糖苷化合物的制备方法
CN112961196B (zh) * 2021-02-07 2022-05-31 中国人民大学 一种糖基和多肽修饰的1,2,3-三唑化合物的制备方法
CN115991702B (zh) * 2021-12-09 2024-02-02 珠海市藤栢医药有限公司 芳基c-葡萄糖苷衍生物、其制备方法及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
DK1385856T3 (da) 2001-04-11 2006-05-15 Bristol Myers Squibb Co Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
PL378324A1 (pl) 2003-01-03 2006-03-20 Bristol-Myers Squibb Company Sposób wytwarzania C-aryloglukozydowych inhibitorów SGLT2
ATE510834T1 (de) * 2003-03-14 2011-06-15 Astellas Pharma Inc C-glykosid-derivate zur behandlung von diabetes
CN104109155A (zh) 2003-08-01 2014-10-22 田边三菱制药株式会社 新颖化合物
EA011158B1 (ru) 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
WO2006108842A1 (en) * 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
KR20120087950A (ko) 2009-10-20 2012-08-07 노파르티스 아게 글리코시드 유도체 및 그의 용도
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
JP6105489B2 (ja) * 2011-02-18 2017-03-29 シャンハイ インリ ファーマシューティカル カンパニー リミティド アリールグルコシド化合物、その調製方法及び使用
EP2725031B1 (en) 2011-06-25 2016-08-03 Xuanzhu Pharma Co., Ltd. C-glycoside derivatives
CN104059042B (zh) 2013-03-22 2017-02-08 正大天晴药业集团股份有限公司 C-三芳基葡萄糖苷类sglt-2抑制剂
CN105017236A (zh) 2014-04-14 2015-11-04 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
CN105001213B (zh) 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用

Also Published As

Publication number Publication date
EP3133071A1 (en) 2017-02-22
CN105001213A (zh) 2015-10-28
CN105001213B (zh) 2020-08-28
EP3133071B1 (en) 2019-12-18
JP2017511383A (ja) 2017-04-20
WO2015158206A1 (zh) 2015-10-22
US9914724B2 (en) 2018-03-13
EP3133071A4 (en) 2017-02-22
US20170037038A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
JP2017511383A (ja) C−アリールグリコシド誘導体、その薬物組成物、調製方法及び応用
US12286430B2 (en) Bcl-2 inhibitor
JP2024517326A (ja) レゾルシノール類、それら製造のための方法、及びその使用
JP4456768B2 (ja) C−配糖体を含有する薬剤
CN104870429B (zh) 苯并呋喃衍生物、其制备方法及其在医药上的应用
TWI457122B (zh) 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物
TWI477497B (zh) 苯并呋喃衍生物
CN104507921B (zh) 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
TW201103535A (en) Carboxylic acid compounds
CN111566102B (zh) 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶
WO2013104257A1 (zh) 多环类衍生物、其制备方法及其在医药上的应用
KR102580087B1 (ko) 자가포식 조절인자(autophagy regulator)로서 사용된 화합물, 및 이에 대한 제조 방법 및 이의 용도
TWI329013B (en) Cannabinoid receptor modulator
CN105017236A (zh) C-芳基糖苷衍生物、其药物组合物、制备方法及应用
CN114072398B (zh) 抑制tdg活性的化合物
CN109824690A (zh) Mcl-1选择性抑制剂及其制备和用途
CN116693525A (zh) 联苯类衍生物及其医药用途
JP4304732B2 (ja) エストロゲンレセプターβアイソフォーム活性化剤
JPH05178850A (ja) ベンゾピラン誘導体、その製法および血圧降下剤
KR20090101275A (ko) 벤조퀴나졸 유도체
WO2024230586A1 (zh) 含二氮杂亚基磺酰结构的化合物作为pkm2激动剂的新用途
KR20250101906A (ko) 아라비노스 유도체 화합물 및 이를 포함하는 퇴행성 뇌질환 예방용 또는 치료용 조성물
KR20250108069A (ko) 아라비노스 유도체 화합물 및 이를 포함하는 퇴행성 뇌질환 예방용 또는 치료용 조성물
CN118812517A (zh) 作为upr激动剂的抗肿瘤化合物及其应用
TW200845993A (en) Novel trifluoromethylphenyltetrahydrocinnoline derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190822

R150 Certificate of patent or registration of utility model

Ref document number: 6577569

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees